Heart Stem Cells Move Closer to Human Treatments
'Patch' for damaged heart is just one of several promising developments
By Amanda Gardner, HealthDay Reporter, Business Week February 24, 2010
There is a wide-spread notion that stem cell therapy is
something of the future. While to date non-hematopoietic uses of stem cells are
not commercially available in the United States, there are numerous clinical
trials ongoing that if successful will allow for FDA registration. In the area
of heart failure substantial progress has been made. We previously discussed
cases from outside of the US, such as that of David Alanis
http://www.youtube.com/watch?v=PcFQeRNuPDo , which was published in the
peer-reviewed medical literature (Ichim et al. Placental mesenchymal and cord
blood stem cell therapy for dilated cardiomyopathy. Reprod Biomed Online. 2008
Jun;16(6):898-905). Recently the consensus in the cardiology community is
that stem cell therapy is becoming closer to mainstream implementation.
"We have seen consistent but modest effects of stem cells
in improving heart function and reverse remodeling of heart," said Dr. Gordon
Tomaselli, a spokesman for the American Heart Association and an associate
professor of medicine at the Johns Hopkins University School of Medicine in
Baltimore.
"I think there's great hope," added Dr. Darwin J. Prockop,
director of the Texas A&M Health Science Center College of Medicine Institute
for Regenerative Medicine at Scott & White in Temple. He continued "The one
good thing that really has come out is that nobody has been harmed by [the stem
cell] therapies."
In November 2009 at the annual meeting of the American
Heart Association in Orlando, several reports of progress in a controlled
setting were discussed. A group from Germany presented data on 35 patients who
received bone-marrow stem cell transplantation concurrently with coronary artery
bypass surgery. According to the authors, the patients achieved "excellent
long-term safety and survival." The same group also showed that 10 patients who
received stem cells from the bone marrow after mitral valve repair surgery also
had improved heart function with documented increases in the ability of the
heart to pump blood. Doctors from Slovenian also presented data demonstrating
bone marrow stem cells induced improved function in patients with heart
failure.
There is some controversy as to the mechanisms of action by
which stem cells help in heart failure. Original studies supported the notion
that bone marrow blood making stem cells, hematopoietic stem cells, can become
heart cells. Subsequently it was found that the bone marrow contains other
types of stem cells that could become heart cells. More recent studies support
that idea that bone marrow stem cells produce chemical signals that instruct the
stem cells already in the heart to accelerate the healing process.
Kevin Eggan, chief scientific officer for the New York Stem
Cell Foundation and associate professor of stem cell and regenerative biology at
Harvard University, commented on two major advances. The first being an
artificial "patch" comprised of stem cells that can be placed on the heart after
an infarct. He stated "People are making very substantial progress in being
able to make those various vascular cells you would need...Transplanting those is
something that will come from all of this."
Another breakthrough in his mind is the use of stem cells
to screen for drugs. Since stem cells can be made into human heart cells in the
test tube, this would allow for scientists and companies to rely less on animal
testing and go directly into human systems. According to Dr. Eggan, "You can do
this in a couple of different ways. Researchers could determine in a laboratory
dish if a drug actually works on heart cells, he said. The other method would
involve manufacturing heart cells for a variety of people to find out which
cells the drugs work on."
To find more information about ongoing clinical trials,
patients may look at
www.clinicaltrials.gov, or for outside of US treatments
www.cellmedicine.com.
|